Amiodarone Dosing for Intraoperative Atrial Fibrillation with Left Ventricular Dysfunction
For a patient with intraoperative atrial fibrillation and left ventricular dysfunction, administer amiodarone as a 150 mg IV bolus over 10 minutes, followed by 1 mg/min infusion for 6 hours (360 mg), then 0.5 mg/min for 18 hours (540 mg), with a maximum total dose of 2.2 grams over 24 hours. 1, 2, 3
Why Amiodarone is the Preferred Agent in This Clinical Context
- Amiodarone is specifically indicated for patients with left ventricular dysfunction because it is relatively safe in structural heart disease, unlike Class IC agents (flecainide, propafenone) which are contraindicated. 4, 2
- The drug provides dual benefits: immediate ventricular rate control (typically after the first 300-400 mg) and potential cardioversion to sinus rhythm, though conversion may take 6-8 hours and often requires ≥1000 mg total dose. 4, 5
Standard IV Loading Protocol
Initial Bolus
- Administer 150 mg IV over 10 minutes as the loading dose. 1, 2, 3
- This initial bolus provides rapid rate control, which is critical in the intraoperative setting. 5
Maintenance Infusion - First 6 Hours
- Follow with 1 mg/min continuous infusion for 6 hours (total 360 mg). 1, 2, 3
- This early maintenance phase continues therapeutic loading while minimizing hypotension risk. 2
Maintenance Infusion - Next 18 Hours
- Continue at 0.5 mg/min for 18 hours (total 540 mg). 1, 2, 3
- The total 24-hour dose should not exceed 2.2 grams. 2, 3
Critical Administration Requirements
- Use a central venous catheter for concentrations >2 mg/mL to avoid peripheral vein phlebitis. 3
- Administer through a volumetric infusion pump (not drop counters, which can underdose by up to 30%). 3
- Use an in-line filter during administration. 3
- Administer in glass or polyolefin bottles containing D5W for infusions exceeding 2 hours. 3
Expected Clinical Response Timeline
- Ventricular rate control typically occurs after the first 300-400 mg (within 1-2 hours of starting therapy). 5, 6
- Cardioversion to sinus rhythm, if it occurs, usually takes 6-8 hours and often requires ≥1000 mg total dose. 4, 1
- In one study of critically ill patients with severe LV dysfunction (EF <15%), 7 of 8 patients reverted to sinus rhythm within 1 hour using 300 mg over 1 hour. 7
Mandatory Monitoring During Infusion
- Continuous ECG monitoring for bradycardia, heart block, and QT prolongation throughout the infusion. 1, 2
- Blood pressure monitoring for hypotension (occurs in 16% of patients receiving IV amiodarone). 2
- Watch for bradycardia (4.9% with IV therapy) and AV block. 2
Special Considerations for Left Ventricular Dysfunction
- Amiodarone is the preferred antiarrhythmic in patients with heart failure or reduced ejection fraction. 2
- Unlike other antiarrhythmics, slow IV amiodarone infusion is hemodynamically well-tolerated even in patients with marked LV dysfunction. 7
- Before cardioversion occurs, expect beneficial heart rate slowing (mean 28%) resulting in improved stroke volume index (mean 49%) and left ventricular stroke work index (mean 61%). 7
- Use with caution as it may cause negative inotropic effects, though this is less pronounced than with other agents. 2
Supplemental Dosing for Breakthrough Arrhythmias
- For breakthrough VF or hemodynamically unstable VT, administer 150 mg supplemental bolus (mixed in 100 mL D5W, infused over 10 minutes). 3
- Do not exceed an initial infusion rate of 30 mg/min. 3
Common Pitfalls to Avoid
- Do not use Class IC agents (flecainide, propafenone) in patients with structural heart disease or LV dysfunction - they are contraindicated. 4, 2
- Avoid rapid bolus administration, which increases hypotension risk; the 10-minute infusion time is critical. 1, 3
- Do not administer through peripheral IV at concentrations >2 mg/mL due to high phlebitis risk. 3
- Recognize that full antiarrhythmic effect takes days to weeks despite adequate serum levels, so patience is required. 1, 2
Contraindications to Verify Before Administration
- Severe bradycardia, second- or third-degree heart block without pacemaker. 1
- Severe hepatic dysfunction. 1
- Baseline QT prolongation with history of torsades de pointes. 1
- Significant lung disease (relative contraindication - use lowest effective dose if no alternative). 2